A Phase 2b Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis and Stage 2-3 Fibrosis
Schattenberg JM, et al. (2026). AASLD The Liver Meeting 2026 (late-breaking abstract).
Summary
A late-breaking conference abstract from AASLD The Liver Meeting 2026. It reports a 381-person randomised, placebo-controlled phase 2b trial (MK-6024-013, NCT05877547) of once-weekly efinopegdutide, a GLP-1 and glucagon receptor dual agonist, in adults with biopsy-proven MASH and stage 2 or 3 fibrosis. At 52 weeks, efinopegdutide resolved MASH without worsening fibrosis in 56% to 63% of participants, compared with 13% on placebo, and the 7 mg dose had the highest rate. The abstract was released on 6 November 2026, ahead of the 9 November presentation, and the trial is sponsored by Merck Sharp & Dohme. This is a conference abstract, not yet a peer-reviewed paper.